Emily E. Hartwell

The paper uses polygenic scores to analyze pleiotropy between psychiatric, medical, and substance use disorders in a deeply phenotyped sample, finding extensive genetic overlap with substance use phenotypes.

This paper combines transdiagnostic and disorder-level GWAS to enhance genetic risk profiles for psychiatric disorders in multi-ancestry samples, identifying novel SNPs and shared genetic variance.

The paper uses polygenic risk scores and phenome-wide association studies to examine pleiotropy in substance use disorders using a deeply phenotyped sample.

This study shows polygenic risk scores for substance use disorders predict substance use milestones and progression, with differences by sex and population group.

This study performs a cross-ancestry meta-analysis of opioid use disorder, identifying 14 loci, including 12 novel ones, and finding significant genetic correlations with psychiatric and neurological traits.

The paper calculates polygenic risk scores for substance use disorders and finds associations with related phenotypes in electronic health records.